TORL BioTherapeutics
TORL BioTherapeutics is a clinical-stage biopharmaceutical company developing antibody-drug conjugates for cancer, anchored by lead asset ixotatug vedotin, a CLDN6-targeted ADC in a registrational Phase 2 study for platinum-resistant ovarian cancer, with pipeline programs targeting DLK1 and hematology indications and research rooted in a UCLA Slamon Research Lab partnership.
- Company typePrivate
- Founded2023
- HeadquartersCulver City, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What TORL BioTherapeutics does
TORL BioTherapeutics LLC is a clinical-stage biopharmaceutical company headquartered in Culver City, California (6100 Bristol Parkway), founded and publicly launched in April 2023 to discover, develop, and commercialize antibody-based therapies for cancer. The company is built around an exclusive research partnership with the Slamon Research Lab at UCLA, which provides a scalable drug-discovery engine for identifying novel antibody targets, antibody candidates, and companion-diagnostic criteria. Its pipeline currently comprises three antibody-drug conjugates (ADCs): the lead asset ixotatug vedotin (Ixo-V; TORL-1-23), a CLDN6-targeted ADC for CLDN6+ solid tumors including platinum-resistant ovarian, non-small cell lung, endometrial, and testicular cancers, currently in a global registration-enabling Phase 2 study (CATALINA-2) with topline data anticipated mid-2027; TORL-4-500, a DLK1-targeted ADC in pre-clinical development; and TORL-5-700, a hematology ADC in early clinical development. All programs target molecular or genetic signatures paired with companion diagnostics to enable patient stratification, and ixotatug vedotin has received FDA Fast Track Designation.
The company's revenue model is contingent on future regulatory approval and commercialization of its ADC pipeline, with no current product revenue disclosed; capital to date has come from multiple venture financings, including a $158M Series B in April 2023 led by Goldman Sachs Asset Management, an oversubscribed $158M Series B-2 in April 2024, and a $96M Series C in October 2025, bringing total funding to over $450M as of May 2026. The go-to-market approach is research-led: TORL advances clinical development through global investigator and clinical-research-network partnerships, generates awareness via presentations at major oncology congresses (ASCO, ESMO), and intends to commercialize through traditional pharmaceutical channels once approved. Its customer set is defined by indication rather than payer, targeting CLDN6-positive cancer patients (starting with platinum-resistant ovarian cancer) and DLK1-positive hematology patients, with the company pairing each therapeutic with a companion diagnostic to ensure the right drug reaches the right patient.
The company is led by CEO Aran Maree, M.D. (formerly CMO at Johnson & Johnson Innovative Medicines, appointed CEO effective May 2026), Chairman Mark Alles (former CEO), CFO/CTO and Co-Founder Dave Licata, CSO Steve Ritland, PhD, COO Christine Loggins, and supported by a board that includes co-founders Dennis Slamon, M.D., PhD (Chief, Hematology-Oncology at UCLA) and Neil O'Brien, PhD (UCLA), alongside representatives from Goldman Sachs Life Sciences, Crescent Capital, Sarah Cannon Research Institute, and PanCAN. The company operates with 51-100 employees and is independently owned by its institutional and strategic investors, with no parent company or controlling entity identified.
TORL BioTherapeutics firmographics
Firmographics- Name
- TORL BioTherapeutics
- Legal name
- TORL BioTherapeutics LLC
- Website
- https://torlbio.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- TORL BioTherapeutics is a clinical-stage biopharmaceutical company developing antibody-drug conjugates for cancer, anchored by lead asset ixotatug vedotin, a CLDN6-targeted ADC in a registrational Phase 2 study for platinum-resistant ovarian cancer, with pipeline programs targeting DLK1 and hematology indications and research rooted in a UCLA Slamon Research Lab partnership.
- Ownership category
- akta.pro rank
TORL BioTherapeutics industry classification
Industry- Product category
- Oncology Biopharmaceuticals
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
- akta.pro secondary industry
- High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA)
Keywords
Where TORL BioTherapeutics is headquartered
LocationHeadquarters
- HQ city
- Culver City
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
TORL BioTherapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Biopharmaceutical Development and Commercialization: Pre-revenue clinical-stage biopharmaceutical company developing antibody-based cancer therapies. Revenue will be generated upon regulatory approval and commercialization of its ADC pipeline. Programs include ixotatug vedotin (TORL-1-23) in pivotal Phase 2 for platinum-resistant ovarian cancer, with additional programs in preclinical and clinical stages targeting CLDN6 and DLK1.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
TORL BioTherapeutics product offering
Product offeringCore offering
TORL BioTherapeutics is a clinical-stage biopharmaceutical company developing antibody-based immunotherapies, primarily antibody-drug conjugates (ADCs), for the treatment of cancer. The company's lead asset, ixotatug vedotin (TORL-1-23), is a CLDN6-targeted ADC currently in pivotal Phase 2 trials for platinum-resistant ovarian cancer. Additional pipeline programs target DLK1 in hematology indications. All programs leverage the company's drug discovery engine developed through a partnership with UCLA's Slamon Research Lab and incorporate companion diagnostics for patient selection.
Product overview
TORL BioTherapeutics is a biopharmaceutical company developing antibody-based therapies for cancer treatment. The company's pipeline includes multiple antibody-drug conjugates (ADCs) and monoclonal antibodies. The lead program is Ixotatug vedotin (TORL-1-23), a CLDN6-targeted ADC in Phase 2 clinical trials for platinum-resistant ovarian cancer and other CLDN6+ solid tumors. Additional pipeline programs include TORL-4-500 (DLK1-targeted ADC in pre-clinical) and TORL-5-700 (ADC for hematology in clinical stage). All programs leverage the company's partnership with UCLA's Slamon Research Lab for biologics-based drug development and include companion diagnostics to ensure targeted patient selection.
Differentiator
Problem solved
Functional benefit
Products and services
- Ixotatug Vedotin (Ixo-V; TORL-1-23) First- and potentially best-in-class clinical-stage antibody-drug conjugate (ADC) targeting Claudin 6 (CLDN6) for the treatment of CLDN6+ solid tumors including ovarian, non-small cell lung, endometrial, and testicular cancers. Has received FDA Fast Track Designation and is being evaluated in the global Phase 2 CATALINA-2 registrational study for platinum-resistant ovarian cancer.
- TORL-4-500 Pre-clinical antibody-drug conjugate (ADC) targeting DLK1 for hematology indications within TORL BioTherapeutics' oncology pipeline.
- TORL-5-700 Clinical-stage antibody-drug conjugate (ADC) targeting an undisclosed indication in hematology within TORL BioTherapeutics' oncology pipeline.
Quantifiable outcome
- 32.1% objective response rate (ORR) and 92.9% disease control rate (DCR) with ixotatug vedotin plus bevacizumab in recurrent ovarian cancer (29 patients)
- +1 more outcomes
Companies that use TORL BioTherapeutics
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
TORL BioTherapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
TORL BioTherapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- UCLA Slamon Research LabcoreUnique drug discovery partnership with Slamon Research Lab at UCLA provides scalable technology platform for identification of promising targets, antibodies and patient selection criteria. Dennis Slamon, MD, PhD, serves as Director and Co-Founder and Chief, Hematology-Oncology at UCLA. Neil O'Brien, PhD, serves as Director and Co-Founder and Associate Professor at UCLA.
- Global Clinical Research NetworkscoreCollaborations with expert clinicians and strategic partnerships with global clinical research networks ensure a streamlined path to bring investigational medicines to patients in need. Conducting pivotal global Phase 2 CATALINA-2 registrational study.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
TORL BioTherapeutics competitors and assessment
Company assessmentEmerging players
- ProfoundBio: Earlier-stage clinical ADC developer focused on oncology with proprietary linker-payload technology, pursuing overlapping solid tumor indications that intersect with TORL's pipeline strategy.
Direct peers
- Mersana Therapeutics: Clinical-stage biopharmaceutical company developing antibody-drug conjugates for oncology, with a similar pipeline-stage profile and platform-based approach to ADC discovery and development as TORL.
- Pyxis Oncology: Clinical-stage oncology biotech developing antibody-drug conjugates and immunotherapies for difficult-to-treat cancers, sharing TORL's profile as a venture-backed, clinical-stage ADC developer.
- ImmunoGen (AbbVie): Develops ADCs for cancer, including ELAHERE for platinum-resistant ovarian cancer — the same indication as TORL's lead ixotatug vedotin — making it the most directly competing clinical and commercial peer in TORL's lead indication.
- Sutro Biopharma: Clinical-stage oncology company with a proprietary cell-free protein synthesis platform for developing ADCs and other antibody-based therapeutics, mirroring TORL's integrated discovery-to-development ADC approach.
- Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing ADCs with immune-stimulating mechanisms for solid tumors, comparable to TORL in stage, modality (ADC), and oncology focus.
Broad incumbents
- Daiichi Sankyo: Global pharmaceutical leader in ADC technology (e.g., Enhertu partnered with AstraZeneca), with broad oncology pipeline and significantly greater resources, making it a key competitive incumbent to TORL's ADC development.
- AstraZeneca: Major oncology incumbent with a large ADC franchise (via Daiichi Sankyo partnership) and active development in ovarian and lung cancers, representing the type of strategic partner/acquirer that may ultimately commercialize or compete with TORL's assets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
TORL BioTherapeutics social profiles
Digital presenceTORL BioTherapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
TORL BioTherapeutics leadership team
Management profileNumber of profiles
Profiles13 records
TORL BioTherapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors17 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TORL BioTherapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TORL BioTherapeutics
What does TORL BioTherapeutics do?
TORL BioTherapeutics is a clinical-stage biopharmaceutical company developing antibody-based immunotherapies, primarily antibody-drug conjugates (ADCs), for the treatment of cancer. The company's lead asset, ixotatug vedotin (TORL-1-23), is a CLDN6-targeted ADC currently in pivotal Phase 2 trials for platinum-resistant ovarian cancer. Additional pipeline programs target DLK1 in hematology indications. All programs leverage the company's drug discovery engine developed through a partnership with UCLA's Slamon Research Lab and incorporate companion diagnostics for patient selection.
Is TORL BioTherapeutics a public or private company?
TORL BioTherapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was TORL BioTherapeutics founded?
TORL BioTherapeutics was founded in 2023. It employs 51 to 100 people.
Where is TORL BioTherapeutics based?
TORL BioTherapeutics is headquartered in Culver City, United States, in the North America region.
How does TORL BioTherapeutics make money?
One revenue line is on record: biopharmaceutical Development and Commercialization.
Who are TORL BioTherapeutics's main competitors?
ProfoundBio is listed as an emerging player. Direct peers are Mersana Therapeutics, Pyxis Oncology, ImmunoGen (AbbVie), Sutro Biopharma and Bolt Biotherapeutics. Broad incumbents are Daiichi Sankyo and AstraZeneca.
Does TORL BioTherapeutics have an API?
No public API is recorded for TORL BioTherapeutics.
What industry is TORL BioTherapeutics in?
TORL BioTherapeutics's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening). Its SIC code is 2834.